Brief: Codiak Initiates Patient Dosing In Phase 1/2 Clinical Trial Of Exosting For The Treatment Of Solid Tumors

Codiak BioSciences,.

01/10/2020 12:45

Oct 1 (Reuters) - Codiak BioSciences Inc  CDAK.O :
    * CODIAK INITIATES PATIENT DOSING IN PHASE 1/2 CLINICAL
TRIAL OF
EXOSTING™ FOR THE TREATMENT OF SOLID TUMORS
    * CODIAK BIOSCIENCES INC - SAFETY, BIOMARKER AND PRELIMINARY
EFFICACY DATA FROM DOSE-ESCALATION PHASE OF EXOSTING TRIAL IS
EXPECTED IN MID-2021
    * CODIAK BIOSCIENCES - INTENDS TO ENROLL FURTHER EXPANSION
COHORTS
OF PATIENTS AT OPTIMAL EXOSTING DOSE TO BE IDENTIFIED IN PHASE 1
PORTION OF CLINICAL PROGRAM

Source text for Eikon:  ID:nBw6DPW51a 
Further company coverage:  CDAK.O 

 ((Reuters.Briefs@thomsonreuters.com;))